{"id":"W2791290180","doi":"10.1016/s1470-2045(18)30144-x","title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":576,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"National Cancer Institute; Kite Pharma; EMD Serono; MacroGenics; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Internal medicine; Oncology; Lung cancer; Anaplastic lymphoma kinase; Response Evaluation Criteria in Solid Tumors; Cohort; Progressive disease; Cancer; Nivolumab; Anaplastic large-cell lymphoma; Immunotherapy; Chemotherapy; Lymphoma; Malignant pleural effusion","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001081132,0.0009442519,0.001755396,0.0002626121,0.0003035236,0.0008855027,0.0006715338,0.0008230084,0.003398377],"category_scores_gemma":[0.0006711701,0.0003584021,0.001552333,0.0002295938,0.0006326055,0.0009517419,0.0003608319,0.002680417,0.0009236711],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009321598,"about_ca_system_score_gemma":0.001162997,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001927123,"about_ca_topic_score_gemma":0.00724331,"domain_scores_codex":[0.9997119,0.00008291371,0.000014417,0.0000613707,0.0000371695,0.0000921119],"domain_scores_gemma":[0.9995162,0.00007859962,0.00008137857,0.00004314431,0.00003952874,0.0002410248],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.793402,0.03050738,0.007406117,0.001156785,0.001990465,0.0001565998,0.0002098237,0.001370945,0.0147563,0.0005039061,0.005629787,0.1429097],"study_design_scores_gemma":[0.7564811,0.2214508,0.01205933,0.00007931679,0.001267024,0.0002542229,0.0001119679,0.001793873,0.001684059,0.000374167,0.004398647,0.00004542434],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9909525,0.003576227,0.000385272,0.0005082026,0.0002481518,0.000830494,0.001054559,0.00007084117,0.002373856],"genre_scores_gemma":[0.9851638,0.003716437,0.001431887,0.001449894,0.0002181629,0.0009695391,0.00268845,0.0000349836,0.004326887],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003398377,"threshold_uncertainty_score":0.01136875,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1328551074004894,"score_gpt":0.452357169030372,"score_spread":0.3195020616298826,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}